Salivary duct carcinoma: A clinopathological report of 11 cases

Huang,Xiaofeng; Hao,Jing; Chen,Sheng; Deng,Runzhi

doi:10.3892/ol.2015.3176

Salivary duct carcinoma: A clinopathological report of 11 cases

Authors:
- Xiaofeng Huang
- Jing Hao
- Sheng Chen
- Runzhi Deng
View Affiliations

Affiliations: Department of Pathology, Affiliated Hospital of Stomatology, Medical School, Nanjing University, Nanjing, Jiangsu 210000, P.R. China, Central Laboratory, Affiliated Hospital of Stomatology, Medical School, Nanjing University, Nanjing, Jiangsu 210000, P.R. China, Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology, Medical School, Nanjing University, Nanjing, Jiangsu 210000, P.R. China
Published online on: May 6, 2015 https://doi.org/10.3892/ol.2015.3176
Pages: 337-341

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to summarize the clinicopathological and immunohistochemical characteristics of salivary duct carcinoma (SDC) and to evaluate the currently available treatment modalities. Between 2001 and 2011, 11 patients with SDC were diagnosed and treated at the Affiliated Hospital of Stomatology of Nanjing University (Nanjing, Jiangsu, China). The present study retrospectively reviewed the clinicopathological and immunohistochemical data of these 11 patients and the results indicated that the parotid gland was the most commonly affected site, followed by the submandibular gland and the palate. Furthermore, the mean age of onset was 58.8 years and all cases were treated with surgery, with 72.7% receiving post‑operative radiation therapy. The range for the follow‑up period was 10‑89 months and of the 11 patients investigated, only two succumbed to the disease. In addition, the two‑year overall survival rate was 75% according to Kaplan‑Meier analysis and the mean overall survival time was 72.8 months. In conclusion, the present study determined that the site of the malignancy is the best predictor of survival in patients with the rare salivary malignancy SDC, while age, gender, T stage, N stage, American Joint Committee on Cancer stage, nerve paralysis, post‑operative radiation, neck dissection, and protein expression levels of Ki‑67, androgen receptor and human epidermal growth factor‑2/neu are less influential factors.

View Figures

View References

1	Kikuchi Y, Hirota M, Iwai T, et al: Salivary duct carcinoma in the mandible: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 103:e41–e46. 2007. View Article : Google Scholar : PubMed/NCBI
2	Barnes L, Eveson JW, Reichart P and Sidransky D: World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumors. IARC Press; Lyon: 2005
3	Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N and Löning T: Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 103:2526–2533. 2005. View Article : Google Scholar : PubMed/NCBI
4	Cornolti G, Ungari M, Morassi ML, et al: Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg. 133:1031–1036. 2007. View Article : Google Scholar : PubMed/NCBI
5	Salovaara E, Hakala O, Bäck L, et al: Management and outcome of salivary duct carcinoma in major salivary glands. Eur Arch Otorhinolaryngol. 270:281–285. 2013. View Article : Google Scholar : PubMed/NCBI
6	Guzzo M, Di Palma S, Grandi C and Molinari R: Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck. 19:126–133. 1997. View Article : Google Scholar : PubMed/NCBI
7	Thompson LD: Salivary duct carcinoma. Ear Nose Throat J. 91:356–359. 2012.PubMed/NCBI
8	Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual. 6th. Springer; New York, NY: 2002
9	Lewis JE, McKinney BC, Weil LH, Ferreiro JA and Olsen KD: Salivary duct carcinoma Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 77:223–230. 1996. View Article : Google Scholar : PubMed/NCBI
10	Barnes L, Rao U, Krause J, Contis L, Schwartz A and Scalamogna P: Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol. 78:64–73. 1994.PubMed/NCBI
11	Jaspers HC, Verbist BM, Schoffelen R, et al: Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol. 29:e473–e476. 2011. View Article : Google Scholar : PubMed/NCBI
12	Laurie SA and Licitra L: Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 24:2673–2678. 2006. View Article : Google Scholar : PubMed/NCBI
13	Moriki T, Ueta S, Takahashi T, Mitani M and Ichien M: Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer. 93:344–350. 2001. View Article : Google Scholar : PubMed/NCBI
14	Kim JY, Lee S, Cho KJ, et al: Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands. Br J Radiol. 85:e947–e952. 2012. View Article : Google Scholar : PubMed/NCBI
15	Nashed M and Casasola RJ: Biological therapy of salivary duct carcinoma. J Laryngol Otol. 123:250–252. 2009. View Article : Google Scholar : PubMed/NCBI
16	de Potter CR: The neu-oncogene: more than a prognostic indicator? Hum Pathol. 25:1264–1268. 1994. View Article : Google Scholar : PubMed/NCBI
17	Skálová A, Stárek I, Vanecek T, et al: Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 42:348–356. 2003. View Article : Google Scholar : PubMed/NCBI
18	Wee DT, Thomas AA and Bradley PJ: Salivary duct carcinoma: what is already known, and can we improve survival? J Laryngol Otol. 126(Suppl 2): S2–S7. 2012.PubMed/NCBI
19	Nagao T, Gaffey TA, Visscher DW, et al: Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol. 28:319–326. 2004. View Article : Google Scholar : PubMed/NCBI
20	Yamamoto H, Uryu H, Segawa Y and Tsuneyoshi M: Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland. Pathol Int. 58:322–326. 2008. View Article : Google Scholar : PubMed/NCBI
21	Johnson CJ, Barry MB, Vasef MA and Deyoung BR: Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Appl Immunohistochem Mol Morphol. 16:54–58. 2008.PubMed/NCBI
22	Nabili V, Tan JW, Bhuta S, Sercarz JA and Head CS: Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 29:907–912. 2007. View Article : Google Scholar : PubMed/NCBI